Table 3. Mortality of cohort from specific cancers, 1946-2012.

Cancera	ICD Codes		All workers				Workers with more than background exposure to styrene
	ICD 9	ICD 10	Deaths observed	Deaths expected	SMR	95%CI	Deaths observed	Deaths expected	SMR	95%CI
Pharynxb	146-149.1	C09-C14.2	9	6.7	1.34	0.61-2.54	7	4.6	1.51	0.61-3.11
Oesophagus	150	C15	47	44.2	1.06	0.78-1.41	35	30.3	1.16	0.80-1.61
Stomach	151	C16	43	57.0	0.75	0.55-1.02	31	36.1	0.86	0.58-1.22
Large intestine	153	C18	49	63.8	0.77	0.57-1.02	36	40.6	0.89	0.62-1.23
Rectum	154	C19-C21	33	39.4	0.84	0.58-1.18	21	25.7	0.82	0.51-1.25
Liverc	155.0-155.1	C22	16	13.6	1.18	0.67-1.91	10	9.4	1.07	0.51-1.96
Pancreas	157	C25	48	42.5	1.13	0.83-1.50	27	27.6	0.98	0.64-1.42
Larynx	161	C32	13	7.6	1.70	0.91-2.91	6	5.2	1.15	0.42-2.50
Lung	162	C33-C34	329	273.6	1.20	1.08-1.34	229	180.2	1.27	1.11-1.45
Melanomab	172	C43	9	10.0	0.90	0.41-1.71	4	6.8	0.59	0.16-1.51
Breast	174, 175	C50	24	31.2	0.77	0.49-1.15	11	11.6	0.95	0.47-1.70
Prostate	185	C61	63	73.0	0.86	0.66-1.10	44	50.7	0.87	0.63-1.17
Bladderb	188	C65-C68	38	32.8	1.16	0.82-1.59	28	21.6	1.29	0.86-1.87
Kidneyb	189	C64	28	21.1	1.33	0.88-1.92	18	14.4	1.25	0.74-1.98
Brain and nervous system	191,192	C71-C72	32	24.5	1.31	0.89-1.84	26	16.7	1.55	1.02-2.28
Hodgkin’s disease	201	C81	2	4.1	0.49	0.06-1.77	2	2.6	0.75	0.09-2.73
Non-Hodgkin lymphomab	200.202.0, 202.1,202.8	C82-C85	24	25.2	0.95	0.61-1.42	14	16.9	0.83	0.45-1.39
Multiple myelomab	203.0	C90	13	13.9	0.94	0.50-1.60	9	9.1	0.99	0.45-1.88
Leukaemia	204-208	C91-C95	23	25.3	0.91	0.58-1.36	13	16.7	0.78	0.42-1.33
Lympho-haematopoietic cancer	200-208	C81-C96	62	69.8	0.89	0.68-1.14	38	46.1	0.82	0.58-1.14

^aData are limited to cancers with at least four deaths observed or expected in the analysis for all workers. Results for other cancers can be found in Supplementary Table S1.

^bBecause of changes in disease classification, the earliest follow-up for these cancers was from 1950.

^cBecause of changes in disease classification, the earliest follow-up for this cancer was from 1958.